Radiological Surveillance Screening in Asymptomatic Succinate Dehydrogenase Mutation Carriers.

Abstract

There has been a significant increase in the availability of testing for pheochromocytoma and paraganglioma (PPGL) germline susceptibility genes. As more patients with genetic mutations are identified, cascade genetic testing of family members is also increasing. This results in identifying genetic predispositions at a much earlier age. With our current understanding of familial PPGL syndromes, lifelong surveillance is required. This review focuses on carriers of succinate dehydrogenase (SDH) mutations. For genetic testing to be proven worthwhile, the results must be used for patient benefit. For SDHx mutations, this should equate to a surveillance program that is safe and removes as much uncertainty around diagnosis as possible. Early identification of these tumors is the goal of any surveillance program, as surgical resection is the mainstay of treatment with curative intent to prevent the morbidity and mortality consequences associated with catecholamine excess, in addition to the risk of malignancy. Modality and frequency of surveillance imaging and how to engage individuals in the process of surveillance remain controversial questions. The data reviewed here and the cumulative advice supports the avoidance of using radiation-exposing imaging in this group of individuals that require lifelong screening.

• Authors: Nicola Tufton, Anju Sahdev, Scott A Akker
• Journal: Journal of the Endocrine Society (J Endocr Soc) Vol. 1 Issue 7 Pg. 897-907 (Jul 01 2017) ISSN: 2472-1972 [Print] United States
• PMID: 29264540 (Publication Type: Journal Article, Review)